Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here we analyzed the therapeutic effect of LBH589, a class I-II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation. Intravenous (i.v.) administration of LBH589 in immunodeficient BALB/c-RAG2γc mice in which human-derived T and B-ALL cell lines were injected induced a significant reduction in tumor growth. Using primary ALL cells, a xenograft model of human leukemia in BALB/c-RAG2γc mice was established, allowing continuous passages of transplanted cells to several mouse generations. Treatment of mice engrafted with T or B-ALL cells with LBH589 induced an in vivo increase in the acetylation of H3 and H4, which was accompanied with prolonged survival of LBH589-treated mice in comparison with those receiving Vincristine and Dexametasone. Notably, the therapeutic efficacy of LBH589 was significantly enhanced in combination with Vincristine and Dexametasone. Our results demonstrate the therapeutic activity of LBH589 in combination with standard chemotherapy in pre-clinical models of ALL and suggest that this combination may be of clinical value in the treatment of patients with ALL.

[1]  J. Minna,et al.  ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia , 2013, Oncogene.

[2]  J. Martinez-Climent,et al.  Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. , 2010, Blood.

[3]  A. Hall,et al.  NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia. , 2010, Leukemia research.

[4]  A. Statnikov,et al.  The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. , 2010, Cancer cell.

[5]  T. Holyoake,et al.  Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. , 2010, Cancer cell.

[6]  S. Richards,et al.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. , 2010, The Lancet. Oncology.

[7]  P. Atadja,et al.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma , 2010, Haematologica.

[8]  Yiguo Jiang,et al.  MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo[a]pyrene. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  G. Garcia-Manero,et al.  Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. , 2010, Blood.

[10]  M. Dobbelstein,et al.  E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis , 2010, Cell Death and Differentiation.

[11]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[12]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[13]  Susan Groshen,et al.  DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines , 2009, BMC Medical Genomics.

[14]  C. Pui.  Toward a total cure for acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Qiang Yu,et al.  miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. , 2009, Genes & development.

[16]  J. Fletcher,et al.  Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. , 2009, Cancer research.

[17]  P. Atadja,et al.  The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines , 2009, The Journal of pathology.

[18]  J. Martinez-Climent,et al.  Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. , 2009, European journal of cancer.

[19]  S. Bates,et al.  Epigenetic Modifiers: Basic Understanding and Clinical Development , 2009, Clinical Cancer Research.

[20]  R. Johnstone,et al.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.

[21]  R. Siebert,et al.  Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. , 2009, Cancer research.

[22]  R. Crazzolara,et al.  Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. , 2009, Blood.

[23]  C. Richard,et al.  Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia , 2009, Leukemia.

[24]  R. Siebert,et al.  Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Kantarjian,et al.  Epigenetics of acute lymphocytic leukemia. , 2009, Seminars in hematology.

[26]  Iannis Aifantis,et al.  γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.

[27]  A. Younes.  Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.

[28]  G. Garcia-Manero.  Demethylating agents in myeloid malignancies , 2008, Current opinion in oncology.

[29]  A. Rossi,et al.  The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. , 2008, Critical reviews in oncology/hematology.

[30]  L. Poling,et al.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage , 2008, Pigment cell & melanoma research.

[31]  J. Sarkaria,et al.  Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. , 2008, Neuro-oncology.

[32]  Leslie L Robison,et al.  Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.

[33]  Terence P. Speed,et al.  Estimation and assessment of raw copy numbers at the single locus level , 2008, Bioinform..

[34]  S. Harrison,et al.  The potential of histone deacetylase inhibitors for the treatment of multiple myeloma , 2008, Leukemia & lymphoma.

[35]  P. Atadja,et al.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.

[36]  J. Issa,et al.  Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia , 2008, Leukemia.

[37]  F. Prósper,et al.  Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. , 2007, Blood.

[38]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[39]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[40]  P. Atadja,et al.  Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. , 2006, Blood.

[41]  R. Siebert,et al.  Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma , 2006, Leukemia.

[42]  Z. Szallasi,et al.  Reliability and reproducibility issues in DNA microarray measurements. , 2006, Trends in genetics : TIG.

[43]  H. G. Einsiedel,et al.  Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia , 2006, Leukemia.

[44]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[45]  J. Hayes,et al.  Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. , 2005, Molecular cell.

[46]  H. Koeffler,et al.  Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. , 2005, Experimental hematology.

[47]  R. Lock,et al.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.

[48]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[49]  K. Becker,et al.  Analysis of microarray data using Z score transformation. , 2003, The Journal of molecular diagnostics : JMD.

[50]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.